Definium Therapeutics (DFTX) Accounts Payables (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accounts Payables data on file, last reported at $7.1 million in Q1 2026.

• Quarterly Accounts Payables rose 214.24% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 214.24% YoY) and the FY2025 annual result came in at $5.3 million, up 166.02% from the prior year.
• Accounts Payables climbed to $7.1 million in Q1 2026 per DFTX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.6 million in Q2 2023 and bottomed at $732000.0 in Q2 2022.
• The 5-year median for Accounts Payables is $3.3 million (2022), against an average of $4.2 million.
• The widest annual swing landed in 2022, when Accounts Payables tumbled 93.17%; it then surged 1071.72% in 2023.
• Tracing DFTX's Accounts Payables over 5 years: stood at $2.1 million in 2022, then jumped by 95.93% to $4.1 million in 2023, then slumped by 51.4% to $2.0 million in 2024, then jumped by 166.02% to $5.3 million in 2025, then surged by 33.29% to $7.1 million in 2026.
• Per Business Quant, the three latest DFTX Accounts Payables figures stand at $7.1 million (Q1 2026), $5.3 million (Q4 2025), and $8.1 million (Q3 2025).

Peer Comparison